Inactive Instrument

Highlights Selectimmune Pharma AB (publ)

Equities

SELECT B

SE0012622785

Highlights

Unlock all the news: Be the first to know and act before the market!

Selectimmune Pharma AB Reports Earnings Results for the Fourth Quarter and Full Year Ended June 30, 2023	29/23/29	CI
Selectimmune Pharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023	25/23/25	CI
Hamlet BioPharma AB (NGM:HAMLET B) completed the acquisition of Selectimmune Pharma AB.	17/23/17	CI
Hamlet Pharma AB (NGM:HAMLET B) agreed to acquire Selectimmune Pharma AB (NGM:SELECT B).	31/23/31	CI
Selectimmune Pharma AB Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022	23/23/23	CI
Selectimmune Pharma AB Reports Earnings Results for the First Quarter Ended September 30, 2022	16/22/16	CI
Selectimmune Pharma Has Successfully Completed Preparations to Start A Controlled Clinical Trial in Patients with Bladder Pain Syndrome	14/22/14	CI
Selectimmune Pharma AB Reports Earnings Results for the Fourth Quarter Ended June 30, 2022	30/22/30	CI
Selectimmune Pharma AB Reports Earnings Results for the Full Year Ended June 30, 2022	30/22/30	CI
Selectimmune Pharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2022	24/22/24	CI
Selectimmune Pharma AB Receives Approval to Conduct A Placebo-Controlled Clinical Study of Bladder Pain	25/22/25	CI
Selectimmune Pharma AB to Conduct Clinical Trials in Cystitis and Bladder Pain Syndrome	30/22/30	CI
Selectimmune Pharma AB Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2021	24/22/24	CI
SelectImmune Pharma AB Files Important Patent Application for Acute Pyelonephritis	01/22/01	CI
Selectimmune Pharma AB Reports Earnings Results for the First Quarter Ended September 30, 2021	18/21/18	CI
Selectimmune Pharma AB Publ Reports Earnings Results for the Fourth Quarter Ended June 30, 2021	31/21/31	CI
Start of the Selectimmune Pharma Phase II Trial of Targeted Immunotherapy in Recurrent Acute Cystitis	30/21/30	CI
SelectImmune Pharma Collaborates with Lonza to Develop an Immunotherapeutic Drug Candidate	21/21/21	CI
Selectimmune Pharma AB Publ Reports Earnings Results for the Third Quarter Ended March 31, 2021	25/21/25	CI
Selectimmune Pharma AB Publ Reports Earnings Results for the Second Quarter Ended December 31, 2020	26/21/26	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Selectimmune Pharma AB (publ)

Equities

SELECT B

SE0012622785

Highlights

Filters